key: cord-0894557-g0kx3g1t
authors: Sparks, Jeffrey A; Singh, Namrata; Wallace, Zachary S
title: Effectiveness of COVID-19 vaccination in immune-mediated inflammatory diseases
date: 2022-04-14
journal: Lancet Rheumatol
DOI: 10.1016/s2665-9913(22)00109-6
sha: cddfe134b8b90b010926943a7f57822d419557b8
doc_id: 894557
cord_uid: g0kx3g1t

nan

The rapid development of safe and effective COVID-19 vaccines was a hallmark achievement in the pandemic. However, patients with immune-mediated inflammatory diseases were excluded from vaccine clinical trials and might be vulnerable to SARS-CoV-2 breakthrough infection due to immunosuppression and altered immunity. 1,2 Indeed, studies showed lower humoral responses after COVID-19 vaccination in these patients than in healthy controls. 3, 4 Although most patients who are immunosuppressed had only a slightly reduced humoral response after COVID-19 vaccination, some medications, such as B cell-depleting therapies, are associated with severely reduced response. 3, 4 There had been no previous systematic evaluation to quantify the effectiveness of COVID-19 vaccination among patients with immune-mediated inflammatory diseases.

In The Lancet Rheumatology, Jessica Widdifield and colleagues 5 report on the effectiveness of COVID-19 vaccination among patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis, and inflammatory bowel disease from Ontario, Canada. Between March 1 and Nov 22, 2021, the authors identified 2127 (5·9%) testpositive cases among 36 145 individuals with rheumatoid arthritis who were tested for SARS-CoV-2, 476 (6·1%) test-positive cases among 7863 individuals with ankylosing spondylitis tested, 3089 (6·5%) test-positive cases among 47 199 individuals with psoriasis tested, and 1702 (5·4%) test-positive cases among 31 311 individuals with inflammatory bowel disease tested. Effectiveness of two doses of mRNA-based COVID-19 vaccines (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) against infection was more than 79% across all diseases. 5 Effectiveness against severe COVID-19 outcomes (defined as admission to hospital or death due to COVID-19) was even higher, ranging 92-97%. 5 These findings will immediately be helpful to clinicians and patients to gauge expectations of protection after vaccination. This might help combat vaccine hesitancy 6 by providing direct evidence that COVID-19 vaccines are highly effective in patients with immune-mediated inflammatory diseases.

Some methodological considerations of this investigation are noteworthy. First, the sample was population based from the entire province of Ontario, and used validated algorithms with high accuracy to identify individuals with the immune-mediated inflammatory diseases studied. The authors were able to link registries to identify dates of vaccine doses, SARS-CoV-2 testing, hospitalisations, and deaths. Second, they used a test-negative design to estimate vaccine effectiveness. This method has previously been reported to protect against bias by limiting the analysis to patients with similar access to and indications for testing, while assuring that the controls did not have COVID-19. 7 Rather than analysing all patients, the authors only examined those who presented for SARS-CoV-2 testing. This approach is a stronger study design than analysing the entire database and assuming that everyone without positive tests did not have COVID-19. Third, the authors examined a number of vaccine doses and the duration between vaccination and testing to look for waning effectiveness. They found moderate effectiveness after a single vaccine dose, but high effectiveness after two or three doses. Although there was some slight waning in effectiveness, vaccination remained highly effective even beyond 120 days after the second dose. Thus, the evidence generated here is rigorous to conclude that COVID-19 vaccines are effective in patients with these immunemediated inflammatory diseases.

Some limitations and future research directions are worth noting. First, the investigators only examined four immune-mediated inflammatory diseases because of limitations in accurately identifying conditions. How one might extrapolate these results to conditions not studied (eg, to systemic lupus erythematosus, or more diverse populations) is not clear. Notably, B-cell depletion, mycophenolate mofetil, and calcineurin inhibitors (each associated with impaired humoral response to vaccination 3,4 ) are not typically used to treat most diseases studied by Widdifield and colleagues, with the exception of some patients with rheumatoid arthritis who might receive B cell-depleting therapy. 8 was unavailable and probably confounds results on an individual level. Patients on B cell-depleting therapies are likely to remain vulnerable even after vaccination. 8, 9 Future studies should assess risk of breakthrough infection associated with specific immunosuppressive medications. Third, most patients included in the study received BNT162b2, so outcomes after receipt of this vaccine drove results. A sensitivity analysis suggested that mRNA-1273 might be even more effective. Future studies should examine differences in different types of vaccines for protection in patients with immune-mediated inflammatory diseases. Fourth, data for the study were collected before the omicron (B.1.1.529) variant wave of the pandemic, when vaccine effectiveness was reported to significantly decrease in the general population, 10 perhaps due to waning vaccine effect, behavioural changes, and evolution away from the ancestral SARS-CoV-2 strain for which vaccines were developed. Thus, repeating similar analyses for variants with longer time since vaccine receipt will be important because vaccine effectiveness is ever-changing with new variants. These future studies might provide rationale for additional vaccine doses for patients who are immunosuppressed or use of novel vaccines against contemporary viral variants. In summary, these important results confirm that the COVID-19 vaccines were highly effective against infection and severity among patients with immune-mediated inflammatory diseases. These findings should encourage continued uptake of COVID-19 vaccination and future research related to waning effects, the effectiveness of additional vaccine doses, and influence of specific immunosuppressive medications. JAS reports consultancy fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, and Gilead unrelated to this work. ZSW reports research support from Bristol Myers Squibb and Principia/Sanofi; consulting fees from Viela Bio, Zenas BioPharma, and MedPace; and participation on a data safety monitoring board and advisory board for Gilead, all unrelated to this work. NS declares no competing interests.

*Jeffrey A Sparks, Namrata Singh, Zachary S Wallace jsparks@bwh.harvard.edu; @jeffsparks

USA (JAS); Department of Medicine

Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases

Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US

Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study

Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immunemediated inflammatory diseases tested between

COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry

Coronavirus disease 2019 outcomes among recipients of anti-CD20 monoclonal antibodies for immunemediated diseases: a comparative cohort study

COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant